ERCC1 expression in triple negative breast cancer


Ozkan C., Gumuskaya B., YAMAN S., AKSOY S., Guler G., Altundag K.

JOURNAL OF BUON, vol.17, no.2, pp.271-276, 2012 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 2
  • Publication Date: 2012
  • Journal Name: JOURNAL OF BUON
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.271-276

Abstract

Purpose: Excision repair cross-complementation group 1 (ERCC1), which is a component of nucleotide excision repair (NER) pathway, removes platinum-induced DNA adducts. Overexpression of ERCC1 has been associated with resistance to platinum-based chemotherapy in ovarian and lung cancers. Detecting ERCC1 overexpression is important in considering treatment options for triple negative breast cancer (TNBC), and in conducting and interpreting trials that search to find specific chemotherapy regimens for TNBC. In this study we aimed to study ERCC1 overexpression in patients with TNBC.